DIA

PTC Therapeutics

PTC Therapeutics appoints Zeldis to board of directors

Thursday, October 4, 2012 12:14 PM

PTC Therapeutics, a biopharmaceutical company based in South Plainfield, N.J., has appointed Jerome B. Zeldis, M.D., Ph.D., to the company's board of directors.

More... »

ACRP Certification Program - July 31st

PTC Therapeutics raises $30M for ataluren in muscular dystrophy

Monday, July 23, 2012 12:36 PM

PTC Therapeutics, a biopharmaceutical company based in South Plainfield, N.J., has completed a $30 million round of financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S and other existing investors.

More... »

CRF Health – eCOA Forum

PTC Therapeutics receives $5 million award from the Wellcome Trust

Friday, December 23, 2011 10:45 AM

PTC Therapeutics has received a $5 million Seeding Drug Discovery (SDD) award from the Wellcome Trust to support the development of small-molecule drugs that target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria. PTC previously received a $5.4 million SDD Award from the Wellcome Trust to support its BMI1 oncology program.

More... »

Roche, PTC sign potential $490m licensing deal

Tuesday, November 29, 2011 01:56 PM

Roche, PTC Therapeutics, and the SMA Foundation, have signed a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) program. SMA is a genetic neuromuscular disorder that causes muscle weakness.

More... »

AstraZeneca, PTC collaborate in oncology

Thursday, June 30, 2011 09:59 AM

AstraZeneca and PTC Therapeutics are joining forces for cancer cures, using PTC's discovery/development technology platform, reported FierceBiotech.  AZ will front an undisclosed amount of cash to work on the first oncology target.

More... »

Stay Granted in Muscular Dystrophy Clinical Trial Case

Friday, September 19, 2008 12:38 PM

The U.S. Court of Appeals for the Third Circuit has granted PTC Therapeutics’ request for a stay of the Federal District Court’s decision on August 20 that would have forced the biotech company to provide its experimental drug PTC124 to 16-year-old Duchenne muscular dystrophy patient Jacob Gunvalson outside its clinical trial process.

More... »

CenterWatch Commentary: Experimental Drug Access Wars Continue

Friday, August 22, 2008 09:00 AM

A U.S. District judge Wednesday ordered PTC Therapeutics to supply its experimental drug to 16-year-old Jacob Gunvalson, who has Duchenne muscular dystrophy, a terminal disease for which there is no known cure.

More... »

Almac Clinical Services
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

June 17

New CISCRP study finds patient perceptions of trial participation safety, motives greatly improved

PwC: Volume and value of pharma, diagnostics deals soar in first quarter, as CRO sector waits on sidelines

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

Operating environment spurs out-of-the-box ideas
High cost, low success rates drive some sponsors to new monitoring, protocol design, patient-centric initiatives

Private equity interest in CROs could lead to more IPOs
Now flush with cash, many PE investors readying to cash out

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs